Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Knee OA Drug's Long-Term safety under watch in small study

NCT ID NCT05752032

ENROLLING_BY_INVITATION Disease control Sponsor: ICM Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Mar 29, 2026 · Last updated May 25, 2026 · Updated 2 times

Summary

This study follows 16 people who previously received the experimental drug ICM-203 or a placebo for knee osteoarthritis. Researchers will track any delayed side effects and measure changes in knee pain and function over time. The goal is to understand the long-term safety and effectiveness of the treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS, KNEE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Barwon Health

    Geelong, Victoria, 3220, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, 5000, Australia

Conditions

Explore the condition pages connected to this study.